Trials / Completed
CompletedNCT00548353
A Study of Gastric Delay in Migraine Patients (3207-003)
A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK3207 | M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets). |
| DRUG | Comparator: Placebo (unspecified) | M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets). |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-04-01
- Completion
- 2010-02-01
- First posted
- 2007-10-23
- Last updated
- 2014-12-19
Source: ClinicalTrials.gov record NCT00548353. Inclusion in this directory is not an endorsement.